Aldeyra has resubmitted its new drug application for reproxalap, an investigational dry eye treatment, which contained new ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

Roche entered into a Licensing, Development, and Commercialisation agreement with Prothena in December 2013 to develop and ...

Experts reassess endpoints, patient selection, targets, and timing for the development of successful immune-based treatments ...

Adults with unresectable stage III or IV melanoma maintained similar progression-free disease control with 1- or 2-year ...

This is a developing news story. Please check back soon for updates. The FDA granted VG801 rare pediatric disease designation ...

In the Phase 3 AFFIRM-AL clinical trial, the primary endpoint of time to all-cause mortality was not met for patients treated with birtamimab. In addition, neither of the secondary endpoints were ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Company will decrease ongoing operating expenses, including an expected substantial reduction in organizational size, and plans to provide a further update in June DUBLIN, May 23, 2025--(BUSINESS ...

Neuroscience technology company Brooklyn Health is using artificial intelligence to target a fundamental problem in neurology ...